Breaking News Instant updates and real-time market news.

DVA

DaVita

$63.20

-0.13 (-0.21%)

06:15
11/29/16
11/29
06:15
11/29/16
06:15

DaVita announces partnership with Rock Health

DaVita announces a partnership with Rock Health, the first venture fund dedicated to digital health and a leader in fostering innovation in healthcare. The partnership will help facilitate direct connections between the diverse, innovative companies in Rock Health's portfolio and DaVita.

  • 06

    Dec

  • 07

    Dec

DVA DaVita
$63.20

-0.13 (-0.21%)

09/20/16
RAJA
09/20/16
UPGRADE
Target $75
RAJA
Outperform
DaVita upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst John Ransom upgraded DaVita to Outperform and established a $75 price target. saying shares have corrected by approximately 18% following Q2 results and concerns about ACA exchange exposure. The analyst views valuation as attractive and thinks ACA exposure is a bit less than previous estimates. Further, investor expectations for DVA Medical Group are low and represent less than 10% EBIT, Ransom wrote.
10/13/16
RHCO
10/13/16
NO CHANGE
RHCO
Price targets cut on dialysis stocks at SunTrust
SunTrust analyst David MacDonald lowered his price targets on dialysis stocks, citing CMS' recent request for information and resulting payor risk and lower assumed multiples. The analyst cut his price target on American Renal Associates (ARA) to $24 from $34, on DaVita (DVA) to $66 from $80 and on Fresenius Medical (FMS) to $48 from $54. He maintains Buy ratings on American Renal and Fresenius but said he does not expect the stocks to rise significantly until the CMS matter is resolved. MacDonald keeps a Hold rating on DaVita.
10/31/16
BARD
10/31/16
NO CHANGE
Target $68
BARD
Outperform
Baird views news from DaVita as 'de-risking event'
Baird analyst Whit Mayo views today's announcement from DaVita as a "de-risking event" with higher than expected patient numbers. The disclosed $230M worst-case operating income hit includes on-exchange and off-exchange patients, and is in the range of what was expected, Mayo tells investors in a research note. DaVita earlier today announced that it will suspend support for applications to the American Kidney Fund for charitable premium assistance by Medicaid patients who are seeking additional coverage through an Affordable Care Act plan. The change will affect approximately 2,000 patients, the company said. To reflect a "scenario for payer mix reversion," Mayo lowered his 2017 earnings per share estimate for DaVita to $4.06 from $4.69. He also cut his price target for the shares to $68 from $85. Mayo keeps an Outperform rating on DaVita, which is trading up 5% to $57.92.
11/01/16
BARD
11/01/16
NO CHANGE
Target $68
BARD
Outperform
DaVita price target lowered to $68 from $85 at Baird
Baird analyst Whit Mayo lowered his price target on DaVita to $68 from $85 following the company's better than feared announcement of its potential $230M hit from on-exchange and off-exchange patients related to a potential CMS ruling regarding charitable premium assistance for ESRD patients. The analyst cut his estimates, although he feels the announcement de-risks the stock. Mayo maintained his Outperform rating on DaVita shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.